Treatment of Pathologic Laughing and Weeping with Amitriptyline

New England Journal of Medicine

Volumn 312, Issue 23, 1985, Pages 1480-1482

  Schiffer, Randolph B ^a   Herndon, Robert M ^a   Rudick, Richard A ^a  

^a STRONG MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; PLACEBO;

ADVERSE DRUG REACTION; ARTICLE; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CRYING; DEPRESSION; DROWSINESS; DRUG DOSE; DRUG THERAPY; FRONTAL LOBE; HUMAN; INTOXICATION; MOUTH; MULTIPLE SCLEROSIS; NERVOUS SYSTEM; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PATHOLOGICAL LAUGHTER; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; THERAPY; XEROSTOMIA;

EID: 0021873322     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198506063122303     Document Type: Article

References (27)

1. Monrad-Krohn GH. On facial dissociation. Acta Psychiatr Neurol 1939; 14: 557–566.
2. Davison C, Kelman H. Pathologic laughing and crying. Arch Neurol Psychiatr 1939; 42: 595–643.
3. Kramer HC. Laughing spells in patients, after lobotomy. J Nerv Ment Dis 1954; 119: 517–522.
4. Ironside R. Disorders of laughter due to brain lesions. Brain 1956; 79: 589–609.
5. Sackheim HA, Greenberg MS, Weiman AL, Gur RC, Hungerbuhler JP, Geschwind N. Hemispheric asymmetry in the expression of positive and negative emotions. Arch Neurol 1982; 39: 210–8.
6. Poeck K. Pathologic laughing and crying. In: Vinken PJ, Bruyn GW, eds. Handbook of clinical neurology. Vol. 2. New York: Wiley Interscience, 1969:356–67.
7. Wolf JK, Santana HB, Thorpy M. Treatment of “emotional incontinence” with levodopa. Neurology (Minneap) 1979; 29: 1435–6.
8. Udaka F, Yamao S, Nagata H, Nakamura S, Kameyama M. Pathologic laughing and crying treated with levodopa. Arch Neurol 1984; 41: 1095–6.
9. Lawson IR, MacLeod RDM. The use of imipramine (Tofranil) and other psychotropic drugs in organic emotionalism. Br J Psychiatry 1969; 115: 281–5.
10. Ross ED, Rush AJ. Diagnosis and neuroanatomical correlates of depression in brain-damaged patients: implications for a neurology of depression. Arch Gen Psychiatry 1981; 38: 1344–54.
11. Schiffer RB, Cash J, Herndon RM. Treatment of emotional lability with low-dosage tricyclic antidepressants. Psychosomatics 1983; 24: 1094–6.
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.
13. Beck AT. Depression: clinical, experimental and theoretical aspects. New York: Harper & Row, 1967.
14. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.
15. Gowers WR. A manual of diseases of the nervous system. 3rd ed. Vol. 2. Philadelphia: Blakiston, 1899:79.
16. Weinstein EA, Bender MB. Integrated facial patterns elicited by stimulation of the brain stem. Arch Neurol Psychiatry 1943; 50: 34–42.
17. Schneider RC, Crosby EC. Stimulation of “second” motor areas in the macaque temporal lobe. Neurology (Minneap) 1954; 4: 612–622.
18. Baldwin M, Frost LL, Wood CD. Investigation of the primate amygdala: movements of the face and jaws. Neurology (Minneap) 1954; 4: 586–598.
19. Votaw C.L. Certain functional and anatomical relations of the comu Ammonis of the macaque monkey. I. Functional relations. J Comp Neurol 1959; 112: 353–382.
20. Kahn EA. On facial expression. Clin Neurosurg 1964; 12: 9–22.
21. Brown TG. Note on the physiology of the basal ganglia and mid-brain of the anthropoid ape, especially in reference to the act of laughter. J Physiol (Lond) 1914; 498: 195–207.
22. Brown JW. Physiology and phylogenesis of emotional expression. Brain Res 1967; 5: 1–14.
23. Johnson TN, Clemente CD. An experimental study of the fiber connections between the putamen, globus pallidus, ventral thalamus, and midbrain tegmentum in cat. J Comp Neurol 1959; 113: 83–102.
24. Nauta WJH, Mehler WR. Projections of the lentiform nucleus in the monkey. Brain Res 1966; 1: 3–42.
25. Bevan P, Bradshaw CM, Szabadi E. Effects of desipramine on neuronal responses to dopamine, noradrenaline, 5-hydroxytryptamine and acetylcholine in the caudate nucleus of the rat. Br J Pharmacol 1975; 54: 285–293.
26. Banerjee SP, Kung LS, Riggi SJ, Chanda SK. Development of β-adrenergic receptor subsensitivity by antidepressants. Nature 1977; 268: 455–6.
27. Andersen J, Aabro E, Gulmann N, Hjelmsted A, Pedersen HE. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortriptyline in patients with Parkinson's disease treated with L-DOPA. Acta Neurol Scand 1980; 62: 210–9.